Danaher (NYSE:DHR) Issues FY 2026 Earnings Guidance

Danaher (NYSE:DHR) issued an update on its FY 2026 earnings guidance on Thursday. The company provided earnings per share (EPS) guidance of 8.450-8.600 for the period, compared to the consensus earnings per share estimate of 8.480. The company issued revenue guidance of -.

Danaher Trading Down 0.5%

Shares of DHR opened at $195.25 on Friday. The company’s fifty day moving average is $188.36 and its 200 day moving average is $195.66. Danaher has a fifty-two week low of $160.93 and a fifty-two week high of $242.80. The stock has a market capitalization of $137.26 billion, a PE ratio of 34.68, a P/E/G ratio of 2.44 and a beta of 0.79. The company has a debt-to-equity ratio of 0.48, a quick ratio of 1.25 and a current ratio of 1.65.

Danaher (NYSE:DHR) last released its quarterly earnings data on Tuesday, July 21st. The conglomerate reported $1.94 EPS for the quarter, beating the consensus estimate of $1.85 by $0.09. Danaher had a net margin of 15.95% and a return on equity of 11.04%. The business had revenue of $6.26 billion during the quarter, compared to analyst estimates of $6.12 billion. During the same quarter last year, the business earned $0.77 earnings per share. Danaher’s quarterly revenue was up 5.5% compared to the same quarter last year. Sell-side analysts expect that Danaher will post 8.53 earnings per share for the current fiscal year.

Danaher Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Friday, July 31st. Investors of record on Friday, June 26th were given a $0.40 dividend. The ex-dividend date was Friday, June 26th. This represents a $1.60 annualized dividend and a yield of 0.8%. Danaher’s dividend payout ratio (DPR) is currently 28.42%.

Wall Street Analyst Weigh In

Several brokerages have weighed in on DHR. JPMorgan Chase & Co. reduced their price objective on Danaher from $275.00 to $245.00 and set an “overweight” rating on the stock in a research note on Wednesday, April 22nd. Morgan Stanley dropped their target price on Danaher from $270.00 to $255.00 and set an “overweight” rating for the company in a report on Wednesday, April 22nd. Rothschild & Co Redburn set a $205.00 target price on Danaher in a research report on Friday, April 17th. Citigroup started coverage on Danaher in a report on Tuesday, May 26th. They set a “buy” rating and a $230.00 price target on the stock. Finally, Deutsche Bank Aktiengesellschaft reaffirmed a “buy” rating and set a $240.00 price objective on shares of Danaher in a research note on Wednesday, July 22nd. One investment analyst has rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and five have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $228.91.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in DHR. JPL Wealth Management LLC purchased a new position in Danaher in the 3rd quarter worth about $25,000. WFA of San Diego LLC purchased a new stake in Danaher in the 2nd quarter valued at about $26,000. Transamerica Financial Advisors LLC grew its stake in Danaher by 216.3% in the 4th quarter. Transamerica Financial Advisors LLC now owns 155 shares of the conglomerate’s stock worth $36,000 after acquiring an additional 106 shares in the last quarter. Birchwood Financial Partners Inc. purchased a new position in shares of Danaher during the fourth quarter worth approximately $41,000. Finally, Quattro Advisors LLC purchased a new position in shares of Danaher during the fourth quarter worth approximately $52,000. 79.05% of the stock is currently owned by institutional investors.

About Danaher

Danaher Corporation (NYSE: DHR) is a global science and technology company that designs, manufactures and markets products and services for the life sciences, diagnostics, and environmental and applied markets. The company organizes its operations into business segments focused on Life Sciences, Diagnostics, and Environmental & Applied Solutions, supplying instruments, reagents, software and related services that support research, clinical testing, biopharmaceutical development, and industrial and environmental monitoring.

Products and services in Danaher’s portfolio include analytical and diagnostic instruments, laboratory consumables and reagents, digital and software solutions for workflow and data management, field and industrial monitoring equipment, and service and maintenance programs.